Concepedia

Stuart D. Shumway

SD

Statistics

Publications

26

Citations

3.5K

H-Index

22

Active since

1998

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

University of Wisconsin–Madison

University of North Carolina at Chapel Hill

Moffitt Cancer Center

University of Wisconsin System

Stuart D. Shumway is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in oncology, life sciences, and medicine.

Publications per year

1998–2019

26

Publications

26

An Unbiased Oncology Compound Screen to Identify Novel Combination Strategies

Jennifer O’Neil, Yair Benita, Igor Feldman et al. · Molecular Cancer Therapeutics · 2016 · 432 citations

Medicine, Oncology, Pharmacology +13

Forced Mitotic Entry of S-Phase Cells as a Therapeutic Strategy Induced by Inhibition of WEE1

Marieke Aarts, Rachel Sharpe, Isaac García-Murillas et al. · Cancer Discovery · 2012 · 329 citations

Life Sciences, Cancer Biology, Oncology +17

MK-1775, a Potent Wee1 Inhibitor, Synergizes with Gemcitabine to Achieve Tumor Regressions, Selectively in p53-Deficient Pancreatic Cancer Xenografts

N.V. Rajeshkumar, Elizabeth De Oliveira, Niki A. Ottenhof et al. · Clinical Cancer Research · 2011 · 279 citations · Full text

Medicine, Oncology, Pharmacology +16

Structure of the Cand1-Cul1-Roc1 Complex Reveals Regulatory Mechanisms for the Assembly of the Multisubunit Cullin-Dependent Ubiquitin Ligases

Seth J. Goldenberg, Thomas C. Cascio, Stuart D. Shumway et al. · Cell · 2004 · 276 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +12

Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors

Suzanne Leijen, Robin M.J.M. van Geel, Anna C. Pavlick et al. · Journal of Clinical Oncology · 2016 · 269 citations · Full text

Medicine, Oncology, Pharmacology +14

1–5 of 26